Literature DB >> 3714579

Total knee arthroplasty in chronic hemophilic arthropathy.

J B Magone, D A Dennis, L D Weis.   

Abstract

Nine total knee arthroplasties were performed in seven patients with either Hemophilia A (factor VIII deficiency) or Hemophilia B (factor IX deficiency) and followed for an average of 52 months. A total condylar prosthesis was used in eight virgin knees and a stemmed variable axis prosthesis was used in one revision case. All knees demonstrated the severe joint destruction and cartilage erosion characteristic of chronic hemophilic arthropathy. The average age at operation was 32 years. All patients were evaluated using the knee disability assessment of The Hospital for Special Surgery. All knees were postoperatively rated as either excellent or good. Pain, function, and range of motion were markedly improved. Postoperative radiographic alignment averaged 4 degrees of valgus with half of the virgin knees demonstrating 1 mm or less of non-progressive tibial radiolucency without clinical loosening. The only complication was hemarthrosis from 37 to 59 months postoperatively. This was thought to be secondary to trauma to residual synovium. Total knee arthroplasty in the hemophiliac is a viable alternative to conventional methods of treatment for chronic arthropathy and expectations for pain relief and functional gain can be high.

Entities:  

Mesh:

Year:  1986        PMID: 3714579     DOI: 10.3928/0147-7447-19860501-09

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  2 in total

1.  Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.

Authors:  Marcus E Carr; Thomas P Loughran; John A Cardea; Wade K Smith; Jan G Kuhn; Maribeth V Dottore
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 2.  Total knee arthroplasty in severe haemophilic patients under continuous infusion of clotting factors.

Authors:  M Rahmé; M Ehlinger; A Faradji; N Gengenwin; J Lecocq; J Sibilia; F Bonnomet
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-11-24       Impact factor: 4.342

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.